Latest news - Duchenne UK
Mother of Reinvention – Duchenne UK features in The Times
Duchenne UK featured in The Times' Rare Disease report this week, with articles from CEO Emily Reuben and Project HERCULES' Fleur Chandler.
Read More
Festive MINI Electric embarks on charity tour, raising money for Duchenne UK
A MINI Electric wrapped in 2,000 smart Twinkly LED lights is starting a five-week tour to spread festive cheer and raise money for Duchenne UK alongside the MS Trust and Alzheimer’s Society.
Read More
DMD Hub team expands
In the last few months, the DMD Hub has recruited two new staff members to work with Emma Heslop, the DMD Hub Manager, and to look at new areas where the DMD Hub can develop support.
Read More
Data from wearable devices approved for use in Duchenne muscular dystrophy clinical trials
The European Medicines Agency (EMA) has approved the first measure collected using a digital wearable device for use in clinical trials for Duchenne muscular dystrophy.
Read More
TREAT-NMD Statement on Stem Cell Tourism
Treat-NMD, the organisation that represents doctors and scientists working in neuromuscular disease, has released an important statement on stem cell tourism.
Read More
Opportunity to join Duchenne UK research team
An exciting opportunity has come up to join our team as a Programme Manager and to play a key role in helping Duchenne UK further its work to find effective treatments for Duchenne muscular dystrophy (DMD).
Read More
Duchenne Research Fund partners with Duchenne UK to transform DMD psychosocial care
The Duchenne Research Fund is awarding a £640,000 grant to fund vital psychosocial care and research as part of the nationwide DMD Care UK programme.
Read More
World Muscle Society 2021 – What we learnt
Duchenne UK’s Research Director, Alessandra Gaeta, attended the World Muscle Society (WMS) conference this September to learn about the latest research in neuromuscular diseases.
Read More
Solid Biosciences report positive data from ongoing DMD gene therapy trial
Life sciences company Solid Biosciences have released data from Phase I/II of their ongoing clinical trial of their gene therapy for Duchenne muscular dystrophy.
Read More